Time-Dependent Apparent Increase in dd-cfDNA Percentage in Clinically Stable Patients Between One and Five Years Following Kidney Transplantation
- PMID: 33001185
- DOI: 10.1093/clinchem/hvaa175
Time-Dependent Apparent Increase in dd-cfDNA Percentage in Clinically Stable Patients Between One and Five Years Following Kidney Transplantation
Abstract
Background: Donor-derived cell-free DNA (dd-cfDNA) is reportedly a valuable tool for graft surveillance following kidney transplantation (KTx). Possible changes in dd-cfDNA(%) reference values over time have not been evaluated. For long-term monitoring after KTx, changes in host cfDNA might represent a biasing factor in dd-cfDNA(%) determinations.
Methods: Plasma samples were obtained (n = 929) 12-60 months after engraftment in a cross-sectional cohort of 303 clinically stable KTx recipients. Total cfDNA(copies/mL), dd-cfDNA(%), and dd-cfDNA(copies/mL) were determined using droplet-digital PCR. Stability of threshold values in these stable KTx recipients over time was assessed by 80th, 85th, and 90th quantile regression.
Results: Upper percentiles of total cfDNA showed a significant decline of -1902, -3589, and -4753 cp/mL/log(month) (P = 0.014, <0.001, and 0.017, respectively), resulting in increasing dd-cfDNA(%) percentiles by 0.25, 0.46, and 0.72%/log(month) (P = 0.04, 0.001, and 0.002, respectively), with doubling of the 85th percentile value by 5 years. In contrast, dd-cfDNA(cp/mL) was stable during the observation period (P = 0.52, 0.29, and 0.39). In parallel increasing white blood cell counts and decreasing tacrolimus concentrations over time were observed. After 5 years, the median total cfDNA was still 1.6-fold (P < 0.001) higher in KTx recipients than in healthy controls (n = 135) and 1.4-fold (P < 0.001) higher than patients with other medical conditions (n = 364).
Conclusions: The time-dependent decrease of host cfDNA resulted in an apparent increase of dd-cfDNA fraction in stable KTx patients. For long-term surveillance, measurement of absolute dd-cfDNA concentrations appears to be superior to percentages to minimize false positive results.
Keywords: Donor-derived cell-free DNA; kidney transplantation; long-term surveillance; subclinical rejection; time-dependent dd-cfDNA thresholds.
© American Association for Clinical Chemistry 2020.
Similar articles
-
Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study.Am J Transplant. 2019 Nov;19(11):3087-3099. doi: 10.1111/ajt.15416. Epub 2019 May 28. Am J Transplant. 2019. PMID: 31062511 Free PMC article.
-
Longitudinal variance of Donor-Derived Cell-Free DNA (dd-cfDNA) in Stable Kidney Transplant (KTx) patients are influenced by donor/recipient variables.Clin Transplant. 2021 Sep;35(9):e14395. doi: 10.1111/ctr.14395. Epub 2021 Jul 4. Clin Transplant. 2021. PMID: 34165192
-
Elevated fractional donor-derived cell-free DNA during subclinical graft injury after liver transplantation.Liver Transpl. 2022 Dec;28(12):1911-1919. doi: 10.1002/lt.26479. Epub 2022 May 9. Liver Transpl. 2022. PMID: 35429207
-
Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury.Nat Rev Nephrol. 2021 Sep;17(9):591-603. doi: 10.1038/s41581-021-00428-0. Epub 2021 May 24. Nat Rev Nephrol. 2021. PMID: 34031575 Review.
-
Donor-Derived Cell-Free DNA in Kidney Transplantation as a Potential Rejection Biomarker: A Systematic Literature Review.J Clin Med. 2021 Jan 7;10(2):193. doi: 10.3390/jcm10020193. J Clin Med. 2021. PMID: 33430458 Free PMC article. Review.
Cited by
-
Donor-Derived Cell-Free DNA as a Non-Invasive Biomarker for Graft Rejection in Kidney Transplant Recipients: A Prospective Study among the Indian Population.Diagnostics (Basel). 2023 Nov 27;13(23):3540. doi: 10.3390/diagnostics13233540. Diagnostics (Basel). 2023. PMID: 38066781 Free PMC article.
-
Donor-Derived Cell-Free DNA for Kidney Allograft Surveillance after Conversion to Belatacept: Prospective Pilot Study.J Clin Med. 2023 Mar 22;12(6):2437. doi: 10.3390/jcm12062437. J Clin Med. 2023. PMID: 36983437 Free PMC article.
-
Comparison of methods for donor-derived cell-free DNA quantification in plasma and urine from solid organ transplant recipients.Front Genet. 2023 Jan 27;14:1089830. doi: 10.3389/fgene.2023.1089830. eCollection 2023. Front Genet. 2023. PMID: 36777723 Free PMC article.
-
Assessment of dd-cfDNA Levels in Clinically Stable Lung Allograft Recipients Beyond the Initial 2 y Posttransplant.Transplant Direct. 2022 Nov 17;8(12):e1411. doi: 10.1097/TXD.0000000000001411. eCollection 2022 Dec. Transplant Direct. 2022. PMID: 36406896 Free PMC article.
-
Donor-derived cell-free DNA as a diagnostic tool in transplantation.Front Genet. 2022 Oct 21;13:1031894. doi: 10.3389/fgene.2022.1031894. eCollection 2022. Front Genet. 2022. PMID: 36339004 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
